Skip to main content
. 2022 Apr 4;23:119. doi: 10.1186/s12859-022-04651-9

Table 1.

Number of samples in each class in discovery and validation cohorts

Class Discovery cohort Validation cohort
Healthy controls (normal) 24 62
Renal cancer (RCC) 20
Pancreatic ductal adenocarcinoma (PDAC) 24 47
Colorectal cancer (CRC) 23
Bladder cancer (BLCA) 20
Breast cancer (BRCA) 25
Lung cancer (LUC) 25 55
Acute myeloid leukemia (AML) 28 35
Total 189 199